Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT ID: NCT06350097
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
582 participants
INTERVENTIONAL
2024-04-29
2032-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study details include:
1. The study duration will be event-driven, with an estimated duration of approximately 9 years.
2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met.
3. The visit frequency will be every 3 weeks during the treatment period.
Note: Participants on osimertinib treatment(osimertinib only arm or who have discontinued Dato-DXd while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression or IP discontinuation. Participants who are receiving osimertinib + Dato-DXd are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
NCT04676477
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
NCT03567642
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
NCT05526755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Osimertinib in combination with Datopotamab Deruxtecan
Participants in this group will receive osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion q3w of Day 1 of every 21-day cycle.
Osimertinib
Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Arm 2: Osimertinib 80 mg QD as oral tablet .
Datopotamab Deruxtecan
Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Arm 2: Osimertinib monotherapy
Participants in this group will receive osimertinib 80 mg QD as oral tablet.
Osimertinib
Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Arm 2: Osimertinib 80 mg QD as oral tablet .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Osimertinib
Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Arm 2: Osimertinib 80 mg QD as oral tablet .
Datopotamab Deruxtecan
Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participant must be ≥ 18 years.
Type of Participant and Disease Characteristics
2. Histologically or cytologically documented nonsquamous NSCLC. NSCLC of mixed histology is allowed if adenocarcinoma is the predominant histology. Mixed small-cell lung cancer and NSCLC histology, and sarcomatoid variant of NSCLC is ineligible.
3. Stage IIIB or IIIC or Stage IV metastatic NSCLC or recurrent NSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative surgery or definitive chemoradiation at the time of randomisation.
4. Participants must not have received prior EGFR TKIs or other systemic therapy for Stage IIIB, IIIC or IV NSCLC.
5. The tumour harbors at least 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other genomic alterations, which may include EGFR T790M, assessed by a CLIA-certified (US sites) or an accredited (outside of the US) local laboratory or by central prospective tissue testing.
6. For participants enrolled in randomisation period, mandatory provision of an unstained, archival tumour tissue sample in a quantity sufficient to allow for central confirmation of the EGFR mutation status.
7. WHO performance status of 0 or 1.
8. At least one lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with CT or MRI and is suitable for accurate repeated measurements.
9. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention.
Sex and Contraceptive/Barrier Requirements
10. Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
11. All races, gender and ethnic groups are eligible for this study.
Exclusion Criteria
2. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of osimertinib.
3. History of another primary malignancy.
4. Spinal cord compression and unstable brain metastases, as defined by Protocol.
5. Clinically significant corneal disease.
6. Has active or uncontrolled hepatitis B or C virus infection, as defined by Protocol.
7. Known HIV infection that is not well controlled, as defined by Protocol.
8. Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible).
9. Resting ECG with clinically abnormal findings, as defined by Protocol.
10. Uncontrolled or significant cardiac disease, as defined by Protocol.
11. Past medical history of ILD/penumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
12. Pulmonary embolism within 3 months of the study enrolment or has severe pulmonary function compromise.
Prior/Concomitant Therapy
13. Prior exposure to any agent including an ADC containing a chemotherapeutic agent targeting topoisomerase I, TROP2-targeted therapy.
Prior/Concurrent Clinical Study Experience
14. Participants with a known history of severe hypersensitivity reactions to either Dato-DXd and osimertinib or any excipients of Dato DXd and osimertinib or drugs with a similar chemical structure or class to DXd and osimertinib.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Fountain Valley, California, United States
Research Site
Los Alamitos, California, United States
Research Site
Los Angeles, California, United States
Research Site
Los Angeles, California, United States
Research Site
Orange, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Monica, California, United States
Research Site
Walnut Creek, California, United States
Research Site
New Haven, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Jacksonville, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Orange City, Florida, United States
Research Site
Honolulu, Hawaii, United States
Research Site
North Chicago, Illinois, United States
Research Site
Fort Wayne, Indiana, United States
Research Site
Bethesda, Maryland, United States
Research Site
Detroit, Michigan, United States
Research Site
Saint Paul, Minnesota, United States
Research Site
Bridgeton, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Webster, Texas, United States
Research Site
Woodway, Texas, United States
Research Site
Fairfax, Virginia, United States
Research Site
Fort Belvoir, Virginia, United States
Research Site
Midlothian, Virginia, United States
Research Site
Seattle, Washington, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Camperdown, , Australia
Research Site
Clayton, , Australia
Research Site
Kogarah, , Australia
Research Site
South Brisbane, , Australia
Research Site
Westmead, , Australia
Research Site
Barretos, , Brazil
Research Site
Natal, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Salvador, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Chongqing, , China
Research Site
Guangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Harbin, , China
Research Site
Hefei, , China
Research Site
Hefei, , China
Research Site
Jinan, , China
Research Site
Jinan, , China
Research Site
Kunming, , China
Research Site
Linhai, , China
Research Site
Ningbo, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Wenzhou, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Xi'an, , China
Research Site
Xuzhou, , China
Research Site
Yangzhou, , China
Research Site
Zhengzhou, , China
Research Site
Zhengzhou, , China
Research Site
Angers, , France
Research Site
Marseille, , France
Research Site
Paris, , France
Research Site
Strasbourg, , France
Research Site
Berlin, , Germany
Research Site
Cologne, , Germany
Research Site
Erfurt, , Germany
Research Site
Frankfurt, , Germany
Research Site
Göttingen, , Germany
Research Site
Immenhausen, , Germany
Research Site
Kiel, , Germany
Research Site
Mainz, , Germany
Research Site
München, , Germany
Research Site
Hong Kong, , Hong Kong
Research Site
Hong Kong, , Hong Kong
Research Site
Jordan, , Hong Kong
Research Site
Lai Chi Kok, , Hong Kong
Research Site
Bangalore, , India
Research Site
Delhi, , India
Research Site
Hyderabad, , India
Research Site
Kolkata, , India
Research Site
Mysuru, , India
Research Site
Nagpur, , India
Research Site
Nashik, , India
Research Site
New Delhi, , India
Research Site
New Delhi, , India
Research Site
Vadodara, , India
Research Site
Varanasi, , India
Research Site
Milan, , Italy
Research Site
Monza, , Italy
Research Site
Orbassano, , Italy
Research Site
Padua, , Italy
Research Site
Parma, , Italy
Research Site
Chūōku, , Japan
Research Site
Fukuoka, , Japan
Research Site
Kashiwa, , Japan
Research Site
Kōtoku, , Japan
Research Site
Niigata, , Japan
Research Site
Osaka, , Japan
Research Site
Osakasayama-shi, , Japan
Research Site
Sapporo, , Japan
Research Site
Sendai, , Japan
Research Site
Wakayama, , Japan
Research Site
Yokohama, , Japan
Research Site
Bystra, , Poland
Research Site
Olsztyn, , Poland
Research Site
Poznan, , Poland
Research Site
Warsaw, , Poland
Research Site
Rio Piedras, , Puerto Rico
Research Site
San Juan, , Puerto Rico
Research Site
Erie, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Namdong-gu, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
A Coruña, , Spain
Research Site
Barcelona, , Spain
Research Site
Granada, , Spain
Research Site
Madrid, , Spain
Research Site
Majadahonda, , Spain
Research Site
Valencia, , Spain
Research Site
Taichung, , Taiwan
Research Site
Tainan, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Dusit, , Thailand
Research Site
Hat Yai, , Thailand
Research Site
Udon Thani, , Thailand
Research Site
Adapazarı, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Goztepe Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
Küçükçekmece, , Turkey (Türkiye)
Research Site
Seyhan, , Turkey (Türkiye)
Research Site
Hanoi, , Vietnam
Research Site
Hà Nội, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Vinh, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509883-89-00
Identifier Type: OTHER
Identifier Source: secondary_id
D516NC00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.